LupusCorner

Benlysta as an Add-On Treatment: German Cohort

Article1 min readUpdated Feb 23, 2025View source ↗
New research examines belimumab, better known by the brand name, Benlysta, as an add-on therapy for people with lupus. Researchers in Germany conducted an observational study of Benlysta use in the real world as an add-on treatment for lupus (SLE). After using Benlysta for 6 months, 78% of people experienced at least a 20% improvement in overall disease activity based on physician judgements. And, 42% experienced great benefit of the drug, defined as over a 50% improvement in physician analysis. Additionally, people were able to use fewer corticosteroids while using Benlysta and decreased unexpected use of health services like the ER. Just published in the December 2016 issue of Rheumatology and Therapy, the results of the OBSErve Germany study mirror previous studies in the United States and Spain. OBSErve is a multinational study program funded by GlaxoSmithKline, the makers of Benlysta.
Was this article helpful?

Still puzzling over something?

The agent has read this article — and everything around it. Ask a follow-up and it answers in seconds.

← Back to Help Center